Skip to main content
. 2022 Sep 9;10(9):1508. doi: 10.3390/vaccines10091508

Figure 1.

Figure 1

Immunopotentiating effects of entolimod adjuvant. (A) IgG anti-MA antibody levels in mice vaccinated with TT-SMA (32 ug) in the presence and absence of alum or entolimod in serum collected at 2, 4, 6, and 8 weeks post initial vaccination. Data are presented as levels of antibody in pooled samples from each group (n = 5/group). (B) Week 10 anti-MA antibody levels across all groups.